Amcor appoints Peter Konieczny as CEO

Konieczny has served as Interim CEO since April 2024

Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain

This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II

National conference on `Universal Access to Health care: Digital Solutions’ at IHC

The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’

Alembic Pharmaceuticals receives USFDA final approval for Albendazole Tablets USP, 200 mg

Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business

TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry

Siegfried opens quality control lab in Minden

The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant

NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage

Roche’s PiaSky approved in the EU for treatment of people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG

MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%